BTK Inhibitors Are The Next Big Race In MS

Drug makers are exploring a class of drugs that have been used successfully in blood cancers as potential new treatments for multiple sclerosis, with the expectation that they could represent a new mechanism of action for treating the chronic neurologic condition. The effort to bring the first Bruton's tyrosine kinase (BTK) inhibitor to market for MS involves many players, with Merck KGaA and Sanofi in the apparent lead and Roche Holding AG and Novartis AG close behind.